行情

NVRO

NVRO

Nevro
NYSE

实时行情|Nasdaq Last Sale

95.00
+5.55
+6.20%
盘后: 95.16 +0.16 +0.17% 16:05 04/02 EDT
开盘
84.01
昨收
89.45
最高
96.11
最低
82.96
成交量
238.16万
成交额
--
52周最高
148.05
52周最低
54.00
市值
30.23亿
市盈率(TTM)
-28.0907
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NVRO价格均价为142.56,最高价位170.00,最低价为100.00。

EPS

NVRO 新闻

更多
  • JP Morgan Maintains Neutral on Nevro, Lowers Price Target to $90
  • Benzinga · 4小时前
  • Canaccord Genuity Maintains Buy on Nevro, Lowers Price Target to $114
  • Benzinga · 4小时前
  • SunTrust Robinson Humphrey Maintains Buy on Nevro, Lowers Price Target to $120
  • Benzinga · 4小时前
  • LK, CCL among premarket losers
  • Seeking Alpha - Article · 6小时前

所属板块

医疗设备、用品及经销
+2.96%
医疗设备和用品
+3.41%

热门股票

代码
价格
涨跌幅

NVRO 简况

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
展开

微牛提供Nevro Corp(NYSE-NVRO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NVRO股票新闻,以帮助您做出投资决策。